Introduction
============

Hepatocellular carcinoma (HCC), which represents an overwhelming majority of liver cancer, is the sixth most widespread cancer all over the world and the third most common cause of cancer-related deaths ([@b1-ol-0-0-9748]). As a health threat to people worldwide and, in particular, to developing countries, its overall 5-year survival rate is 5--9% ([@b2-ol-0-0-9748]). However, with early diagnosis and curative resection, the 5-year survival rate can be increased to 69% ([@b3-ol-0-0-9748]). Hence, a diagnostic biomarker with high efficacy is urgently needed. In current clinical work, HCC detection often hinges on a-fetoprotein (AFP), which is the most general biomarker for HCC detection. An aberrant high AFP expression level is frequently observed in HCC patients, with a sensitivity of 39--65% and a specificity of 76--94% ([@b4-ol-0-0-9748]). In addition, some researchers have reported that the ability of AFP to identify and differentiate HCC from non-cancerous hepatopathy is unsatisfying ([@b5-ol-0-0-9748]--[@b7-ol-0-0-9748]).

MicroRNAs (miRNAs) are a sequence of short noncoding RNAs that are \~20--22 nucleotides in length. They post-transcriptionally regulate the gene level by combining with their target mRNAs and play important administrative roles in a variety of biological processes ([@b8-ol-0-0-9748]--[@b12-ol-0-0-9748]). During the past few years, aberrant expression of miRNAs for the early discovery of HCC has been widely verified with inconsistent results. Since then, the significant high expression of miR-15b-5p in HCC patients has been demonstrated by multiple studies ([@b13-ol-0-0-9748],[@b14-ol-0-0-9748]). Liu *et al* ([@b15-ol-0-0-9748]) detected miR-15b-5p in HCC with an AUC of 0.485 (98.25% sensitivity, 15.25% specificity). In another study, Chen *et al* ([@b16-ol-0-0-9748]) revealed that the AUC value of miR-15b-5p for HCC detection was 0.654 (68.1% sensitivity, 79.0% specificity), 0.871 (87.2% sensitivity, 74.2% specificity), and 0.765 (68.1% sensitivity, 80.0% specificity), respectively, in subgroups of HCC vs. liver cirrhosis patients, HCC vs. healthy controls, as well as HCC vs. liver cirrhosis and healthy controls. In fact, the clinical effects of miR-15b-5p on HCC have been reported by only three research groups: i) Hung *et al* ([@b14-ol-0-0-9748]) first analyzed the role of miR-15b-5p in the early diagnosis of HCC. They found that when dysplastic nodules (DN) progressed to HCC (n=10), miR-15b-5p levels significantly increased and the serum level of miR-15b-5p in 120 patients with early HCC was also upregulated as compared to that of 30 patients with chronic hepatitis B using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). ii) Liu *et al* ([@b15-ol-0-0-9748]) detected the serum levels of 29 hepatitis B carriers, 57 patients with HCC and 30 healthy controls also using RT-qPCR. They revealed that the expression of miR-15b-5p was significantly higher in all HCC samples. iii) Chen *et al* ([@b16-ol-0-0-9748]) detected the expression level of miR-15b-5p in 37 patients with HCC, 29 patients with cirrhosis, and 31 healthy controls by RT-qPCR, and the results revealed that the plasma levels of miR-15b-5p in HCC patients were higher than in the other 2 groups (P\<0.05). However, these studies were inconsistent their miR-15b-5p multiple ability indexes. To improve this issue, a meta-analysis of miR-15b-5p in patients with HCC grounded in data gathered from the Gene Expression Omnibus (GEO; <http://www.ncbi.nlm.nih.gov/geo/>) and The Cancer Genome Atlas (TCGA; <http://cancergenome.nih.gov/>) were utilized to evaluate the clinical effectiveness of miR-15b-5p. Bioinformatics analyses were also utilized to investigate the mechanism of miR-15b-5p in HCC. The framework of this study is displayed in [Fig. 1](#f1-ol-0-0-9748){ref-type="fig"}.

Materials and methods
=====================

### Excavation of TCGA and GEO

In TCGA, HCC-related resources with entries named liver hepatocellular carcinoma (LIHC) were downloaded, correlated miRNA-Seq profiles were provided and miR-15b-5p levels were extracted. To normalize the expression level of miR-15b-5p in different trials, data were log~2~-scaled afterwards. Expression data sets of miR-15b-5p were attained from the GEO database, and the expression levels of miR-15b-5p in other types of hepatic tissues were also gathered as the control group as well as miR-15b-5p in HCC. Aimed at more precisely assessing the potential value of miR-15b-5p, the inclusion criteria extended to various non-cancerous samples. Microarrays concerning cell lines and other species were excluded because they did not conform to our study. Based on the expression levels of miR-15b-5p in GEO and TCGA, GraphPad Prism 6.0 (GraphPad Software, Inc., La Jolla, CA, USA) was used to generate the scatter plots and ROC. Additionally, HCC patients obtained from TCGA were utilized to analyze the corresponding clinical information.

### Literature search

Relevant literature was read and gathered from PubMed (<https://www.ncbi.nlm.nih.gov/pubmed/>), Web of Science (<https://clarivate.com/products/web-of-science/>), Ovid (<http://www.ovid.com/site/index.jsp>), EBSCO (<https://www.ebsco.com/products/research-databases>), Embase (<https://www.elsevier.com/solutions/embase-biomedical-research>), Cochrane Library (<https://www.cochranelibrary.com/>), Chinese CNKI (<http://www.cnki.net/>), China Biology Medicine disc, the Chinese Chong Qing VIP (<http://en.cqvip.com/>), and the Chinese Wan Fang (<http://eng.med.wanfangdata.com.cn/>). No language limitations were imposed. The following combination of terms with two sets of keywords were screened by combining the underlying searching strategies: (miR-15b OR miRNA-15b OR micrORNA-15b OR miR15b OR miRNA15b OR microRNA15b OR 'miR 15b' OR 'miRNA 15b' OR 'microRNA 15b' OR miR-15b-5p OR miRNA-15b-5p OR micrORNA-15b-5p OR micrORNA-15b OR miR-15b-5p) AND (malignan\* OR cancer OR tumor OR tumour OR neoplas\* OR carcinoma) AND (hepatocellular cancer OR hepatocellular tumor OR hepatocellular carcinoma OR hepatocellular neoplasm OR liver cancer OR liver tumor OR liver carcinoma OR liver neoplasm OR HCC). Human studies were limited to our literature searches. To confirm the qualified studies, the relevant studies and other references of the review papers were included to avoid missing related studies. Sufficient HCC data and control groups were required to obtain true positives (TPs), false positives (FPs), false negatives (FNs), and true negatives (TNs).

### Potential target gene collection and bioinformatics analyses

To further investigate the regulatory mechanism of miR-15b-5p in HCC, MiRWalk2.0 (<http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/>), which combines 12 online prediction programs, was used to provide comprehensive potential targets for miR-15b-5p. Genes identified by \>4 prediction software programs for miR-15b-5p were selected to obtain more reliable targets. The selected predicted target genes were further intersected with TCGA differentially expressed genes. The overlapping genes were considered to be potential target genes of miR-15b-5p. We combined the two parts of the target genes of miR-15b-5p for further gene functional enrichment analyses. In addition, the genes were input to the STRING version 10.0 online tool (<http://string-db.org/>) to construct the protein-protein interaction (PPI) network.

DAVID 6.8 (<https://david.ncifcrf.gov/>) was applied for gene ontology (GO; <http://geneontology.org/>) and Kyoto Encyclopedia of Genes and Genomes (KEGG; <http://www.genome.jp/kegg/>) pathway analysis. GO was composed of three sections: Molecular function (MF), cellular component (CC) and biological process (BP). The top ten terms of each GO category and marked KEGG pathways were visualized as GO maps and KEGG maps ([@b17-ol-0-0-9748],[@b18-ol-0-0-9748]). Protein expression of hub genes was validated by The Human Protein Atlas (HPA; [www.proteinatlas.org](www.proteinatlas.org)), an immunohistochemistry (IHC) database. The IHC images are publicly available.

### Diagnostic test and statistical analysis

Diagnostic tests were conducted to assess the efficacy of miR-15b-5p in HCC. To thoroughly determine its clinical potential, analyses were carried out between HCC patients and controls, including healthy controls, non-cancerous controls, adjacent non-neoplastic hepatic tissues, HBV^+^/HCV^+^ controls and liver cirrhosis controls. The efficiency of miR-15b-5p in the serum/plasma and tissues was also examined. Stata 12.0 (<https://www.stata.com/stata12/>) was used to detect publication bias, and the standard mean difference (SMD) was used to calculate the outcome from GEO and TCGA. The remaining analyses were accomplished by Meta-DiSc 1.4. P\<0.05 was recognized as statistically significant. The summary receiver operator characteristic (SROC) curve was plotted according to the included studies. A meta-analysis was carried out using a random effects model, including SEN, SEP, diagnostic odds ratio (DOR), positive likelihood ratio (PLR), and negative likelihood ratio (NLR). In addition, the I2 index and χ^2^ test were used to evaluate the heterogeneity in the study. If the I^2^ value was over 50% or P-values of the χ^2^ test were \<0.05, heterogeneity would be shown. Finally, Deek\'s funnel plot was displayed to assess the publication bias.

Results
=======

### Qualified studies and dataset

A total of 3,310 relevant articles were acquired from the aforementioned online databases by a primary search. After removing the duplicated articles as well as screening titles, abstracts and full texts, 2 studies were eventually included, and both were published in English ([@b15-ol-0-0-9748],[@b19-ol-0-0-9748]). The chosen studies provided data from 114 HCC patients and 119 people as controls.

According to our criteria, 11 microarray datasets from GEO were evaluated as eligible, consisting of 512 HCC tissue samples and 287 control samples. Sequencing data in TCGA were based upon 425 samples, with 375 diagnosed HCC samples and 50 control samples, as shown in [Table I](#tI-ol-0-0-9748){ref-type="table"} ([@b20-ol-0-0-9748]--[@b27-ol-0-0-9748]).

### Overall assessment of the diagnostic value and diagnostic meta-analysis

For a more comprehensive understanding of the efficiency of miR-15b-5p in HCC, the eligible 11 GSE chips that we searched were included in our meta-analysis. The expression levels that correlated with miR-15b-5p in GEO and TCGA were also displayed in [Fig. 2](#f2-ol-0-0-9748){ref-type="fig"}. TCGA and 11 GEO profiles with an AUC were presented in [Fig. 3](#f3-ol-0-0-9748){ref-type="fig"}. To further explore the clinicopathological features of miR-15b-5p in TCGA, all of the clinicopathological features mentioned in the chips were collected to investigate their correlation with the miR-15b-5p expression level, the results of which are provided in [Table II](#tII-ol-0-0-9748){ref-type="table"}. No noteworthy relationships were observed between miR-15b-5p expression and the clinicopathological characteristics. Compared with the non-neoplastic controls, the miR-15b-5p levels in HCC revealed that the pooled AUC, SEN, SPE, PLR, NLR and DOR were 0.81 (Q\*=0.74), 0.72 (95% CI: 0.69--0.75), 0.68 (95% CI: 0.65--0.72), 3.18 (95% CI: 1.83--5.51), 0.43 (95% CI: 0.35--0.54), and 8.98 (95% CI: 4.30--18.76) ([Fig. 4](#f4-ol-0-0-9748){ref-type="fig"}), Furthermore, subgroup analyses with both SMD and sROC methods were performed. The subgroups included sample sources (tissues and serum/plasma) and control types (healthy controls, adjacent non-cancerous hepatic tissues, HBV^+^ or HCV^+^ tissues, liver cirrhosis tissues, and those combining HBV^+^/HCV^+^ and cirrhosis). The results were presented from [Fig. 5](#f5-ol-0-0-9748){ref-type="fig"} to [Fig. 12](#f12-ol-0-0-9748){ref-type="fig"}. The control types in healthy people and HBV^+^ or HCV^+^ patients had a favorable diagnostic accuracy with AUC-SROC over 0.9, respectively, when in tissues, serum/plasma, adjacent non-cancerous hepatic tissues, liver cirrhosis and combined HBV^+^/HCV^+^ and cirrhosis were used as the control. The AUC in the ROC curve was over 0.7.

With the random-effects model, forest-plots were generated to represent significant differences in expression between HCC and non-neoplastic control tissues. The pooled SMD (0.62, 95% CI: 0.21, 1.03) is presented in [Fig. 12A](#f12-ol-0-0-9748){ref-type="fig"}. The results of pooled SMD between HCC and tissues, healthy subjects, adjacent non-cancerous hepatic tissues, HBV^+^ or HCV^+^ patients, liver cirrhosis, and HBV^+^/HCV^+^ combined with cirrhosis were displayed in [Fig. 12](#f12-ol-0-0-9748){ref-type="fig"}. The expression level of miR-15b-5p in HCC samples was markedly overexpressed than in non-HCC tissues samples. Moreover, the Deek\'s funnel plot asymmetry test was carried out with STATA 12.0, and no publication bias was detected apart from healthy people and HBV^+^ or HCV^+^ patients. (P\<0.05) ([Fig. 13](#f13-ol-0-0-9748){ref-type="fig"}).

### Potential target genes and bioinformatics annotation

Nine thousand seven-hundred-eighty target genes appearing ≥4 times in 12 prediction methods were regarded as probable target genes of miR-15b-5p from miRWalk. Furthermore, downregulated expressed genes assembled from TCGA were integrated to generate the intersection of target genes, which had more potential to be the real targets of miR-15b-5p in HCC. After 9,780 potential target genes and 1,123 TCGA differentially expressed genes were analyzed for intersection, 225 co-predicted genes from the following bioinformatics analyses were established. In respect to the bioinformatics analyses, 'Prostate cancer' (P=1.56×10^−3^), 'Proximal tubule bicarbonate reclamation' (P=4.10×10^−3^), 'Complement and coagulation cascades' (P=1.68×10^−2^), 'Metabolic pathways' (P=2.18×10^−2^), 'Valine, leucine and isoleucine degradation' (P=2.94×10^−2^), 'Rap1 signaling pathway' (P=3.06×10^−2^), 'Arginine biosynthesis' (P=3.26×10^−2^) and 'FoxO signaling pathway' (P=4.28×10^−2^) ([Table III](#tIII-ol-0-0-9748){ref-type="table"}, [Fig. 14A](#f14-ol-0-0-9748){ref-type="fig"}) were recognized as the most enriched KEGG pathways. For the results of GO pathway analysis in DAVID, the potential targets of miR-15b-5p were notably associated with 'heart trabecula formation' (P=5.26×10^−4^), 'extracellular space' (P=4.20×10^−3^) and 'interleukin-1 receptor activity' (P=2.79×10^−3^) ([Table IV](#tIV-ol-0-0-9748){ref-type="table"}; [Figs. 14B](#f14-ol-0-0-9748){ref-type="fig"} and [15](#f15-ol-0-0-9748){ref-type="fig"}). A PPI network of the 225 genes was constructed in the present study with 224 nodes and 221 edges. In the network, ACACB, RIPK4, MAP2K1, TLR4, and IGF1 were identified as the hub target genes of miR-15b-5p due to the highest significance ([Figs. 16](#f16-ol-0-0-9748){ref-type="fig"}--[18](#f18-ol-0-0-9748){ref-type="fig"}). In the respect to the bioinformatics analyses with these hub genes, the 'activation of MAPK activity' (P=2.39×10^−4^), 'ATP binding' (P=4.17×10^−2^) were regarded as the most significant GO categories. The pathways of 'HIF-1 signaling pathway' (P=5.92×10^−4^), 'Proteoglycans in cancer' (P=2.45×10^−3^) and 'PI3K-Akt signaling pathway' (P=7.21×10^−3^) were considered to be the most significant pathways as assessed by KEGG ([Tables V](#tV-ol-0-0-9748){ref-type="table"} and [VI](#tVI-ol-0-0-9748){ref-type="table"}). We also ascertained the downregulation of ACACB, RIPK4, MAP2K1, TLR4 and IGF1 in HCC tissues via TCGA data. To verify the possibility that these hub genes were targeted by miR-15b-5p, we further revealed the protein levels of ACACB, RIPK4, MAP2K1, TLR4 and IGF1 in HCC tissues and normal tissues. As revealed in [Fig. 19](#f19-ol-0-0-9748){ref-type="fig"}, ACACB had medium staining and moderate intensity in cytoplasmic/membranous normal liver tissues. MAP2K1, TLR4 and IGF1 exhibited low staining and weaker intensity in cytoplasmic/membranous normal liver tissues. In addition, all these hub genes had a lower staining and weaker intensity in HCC tissues. These findings warrant further validation, as limited sample size is provided by the HPA.

Discussion
==========

In the present study, the results of the investigation demonstrated an overall moderate test performance of miR-15b-5p with respect to its clinical value. The summary sensitivity of the plasma/serum miR-15b-5p (81%) revealed superiority compared to AFP despite an overall sensitivity of less than 60%. The AUC value was 0.83 in serum and 0.82 in tissue. Data comparing HCC with non-HCC tissue in the same liver or others controls indicated different factors. In our study, detection of miR-15b-5p in serum/plasma sample had a more favorable diagnostic accuracy than that in tissues. The results also revealed via SMD analysis, that the miR-15b-5p expression level in HCC was markedly overexpressed when compared to non-HCC tissues samples. In detail, the random-effects model was used for the pooled SMD of miR-15b-5p to resolve the problem of heterogeneity. Furthermore, to decrease the heterogeneity, we also performed subgroup analyses with both SMD and sROC methods. The subgroups included sample sources (tissues and serum/plasma) and control types (healthy controls, adjacent non-cancerous hepatic tissues, HBV^+^ or HCV^+^ tissues, liver cirrhosis tissues, and those combining HBV^+^/HCV^+^ and cirrhosis), which revealed that miR-15b-5p may be a prospective biomarker to distinguish HCC patients from healthy people. Numerous HCC patients have a background of liver cirrhosis and chronic HBV and/or HCV. Whether circulating miR-15b-5p can be used to differentiate HCC from benign hepatic lesions has been studied ([@b16-ol-0-0-9748]). Furthermore, our analysis of the studies indicated that the summary sensitivity and specificity of miR-15b-5p for distinguishing HCC from chronic HBV and/or HCV as well as liver cirrhosis were 60 and 80%, respectively, indicating a potential value that was worth exploring. It is regrettable that there is no evidence that miR-15b-5p is related to the progression of HCC, which is worthy of further study.

Some studies have revealed that circulating miRNAs can be potential markers for HCC determination. These miRNAs have been reported to be deregulated in cirrhosis and during development of hepatic malignancy. Abdalla *et al* summarized the tested diagnostic accuracy of miR-618 and miR-650 in HCC which were revealed to be 0.71 and 0.70, and may be of great value for the early diagnosis of HCC ([@b28-ol-0-0-9748]). Tan *et al* reported that serum miR-206, miR-141-3p, miR-433-3p, miR-1228-5p, miR-199a-5p, miR-122-5p, miR-192-5p and miR-26a-5p were potential circulating markers for the diagnosis of HCC with AUC from 0.53--0.73 ([@b29-ol-0-0-9748]). In the current study, compared with the non-neoplastic controls, the miR-15b-5p levels in HCC revealed a favorable diagnostic value with a pooled AUC of 0.81 which indicated that miR-15b-5p may be a prospective biomarker to distinguish HCC patients from non-HCC controls. Our studies on miR-15b-5p in HCC are limited and the role of miR-15b-5p remains largely unknown. The main limitation of this study was that the sample size was small and present findings should be validated in trials with more cases.

With regards to the existing related literature, there were 3 studies that addressed the clinical potential of miR-15b-5p. Hung *et al* ([@b14-ol-0-0-9748]) first indicated that miR-15b-5p could be utilized for the early detection of HCC. However, no explicit diagnostic test was conducted in this study. The study of Liu *et al* ([@b15-ol-0-0-9748]) noted that binding of miR-130b and miR-15b-5p could improve the accuracy of HCC diagnosis based on expression data collected from HCC patients, HBV carriers and healthy controls. Chen *et al* ([@b16-ol-0-0-9748]) designed three subgroups including HCC patients, cirrhosis patients and healthy individuals to evaluate the clinical potential of miR-15b-5p. Only two genes: OIP5 and Rab1A have been revealed to be the direct targets of miR-15b-5p in HCC, however, the existing studies solely concentrated on the performance of circulating miR-15b-5p. Therefore, we collected expression profiles in hepatic tissues to broaden the spectrum of research and carried out a comprehensive analysis.

In bioinformatics analyses, KEGG analysis highlighted the insulin signaling pathway, which was connected with other enriched pathways in our analysis. Insulin can induce phosphorylation of the insulin receptor substrate (IRS), thus allowing IRS to interact with the PI3K/Akt signaling pathway and MAPK signaling pathway, which are involved in biological mechanisms, such as glycogen synthesis, cell glucose intake, protein synthesis and gene transcription ([@b30-ol-0-0-9748]). In HCC, aberrantly elevated insulin receptor and IRS-1 were demonstrated to have a correlation with tumorigenesis contributing to precancerous liver glycogenosis and hepatocellular proliferation ([@b31-ol-0-0-9748]--[@b33-ol-0-0-9748]). Tanaka *et al* also reported that IRS-1 could impede transforming growth factor β1-induced cell apoptosis, which may increase the risk of HCC ([@b34-ol-0-0-9748]). In association with IRS-1, the PI3K/Akt signaling pathway and MAPK signaling pathway were also considered to play roles in the molecular mechanism of HCC, and the joint effect of these pathways was also investigated by researchers. Liang *et al* ([@b35-ol-0-0-9748]) reported that *aconitum coreanum* polysaccharide inhibited the expression of pituitary tumor transforming gene 1, an oncogene, by suppressing the PI3K/Akt signaling pathway and upregulating the MAPK signaling pathway. A study from Gedaly *et al* ([@b36-ol-0-0-9748]) also discovered that targeting the PI3K/Akt signaling pathway and MAPK signaling pathway could attenuate the proliferation of HCC cells. Moreover, these two signaling pathways were also revealed to have independent correlations with HCC cell growth ([@b37-ol-0-0-9748],[@b38-ol-0-0-9748]) apoptosis ([@b39-ol-0-0-9748],[@b40-ol-0-0-9748]) migration, and invasion, as well as adhesion ([@b41-ol-0-0-9748]--[@b43-ol-0-0-9748]), which affects the tumorigenesis and progression of HCC ([@b44-ol-0-0-9748],[@b45-ol-0-0-9748]) via various genes. Therefore, we concluded that miR-15b-5p may participate in hepatocellular carcinogenesis via diverse pathways.

However, certain limitations still exist in our study. Significant heterogeneity was considered in our meta-analysis. The sample types, study design, population, sample size and some of the clinical characteristics may contribute to the increased heterogeneity. Furthermore, overexpression of miR-15b-5p has been previously reported in other malignancies, such as colorectal cancer ([@b46-ol-0-0-9748]), endometrial endometrioid adenocarcinoma ([@b47-ol-0-0-9748]) and non-small cell lung cancer ([@b48-ol-0-0-9748]). In summary, we confirmed that increased miR-15b-5p may not be particularly connected with HCC itself, however it affects the progression of different cancers. For this reason, in daily clinical practice, miR-15b-5p alone may not play an essential role for HCC, however if it is used in combination with other markers, this biomarker may improve test performance.

To conclude, a high miR-15b-5p level may be one the probable causes of HCC tumorigenesis, however, it could also be the consequence after HCC has already occurred, which warrants further investigation. Based on the marked upregulation of the level of miR-15b-5p in HCC, its potential clinical value is anticipated, which also requires practical validation. Notably, the prospective role and signaling pathways of miR-15b-5p have been revealed by *in silico* methods only, and thus, the specific mechanism of miR-15b-5p in HCC requires further study.
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![KEGG and GO analysis of miR-15b-5p target genes. (A) KEGG analysis of the miR-15b-5p target genes. (B) GO functional annotation according to the putative target genes of miR-15b-5p in HCC. KEGG, Kyoto Encyclopedia of Genes and Genomes; GO, Gene ontology; HCC, hepatocellular carcinoma](ol-17-02-1695-g13){#f14-ol-0-0-9748}

![GO functional annotation according to the putative target genes of miR-15b-5p in HCC using the BiNGO plugin in Cytoscape. GO, Gene ontology; HCC, hepatocellular carcinoma.](ol-17-02-1695-g14){#f15-ol-0-0-9748}

![PPI network of the target genes of miR-15b-5p. A total of 224 nodes and 221 edges composed the network. The graph hides the disconnected nodes in the network and the top 5 hub genes with the most interaction lines in PPI analysis. PPI, protein-protein interactions.](ol-17-02-1695-g15){#f16-ol-0-0-9748}

![mRNA expression levels of three hub target genes of miR-15b-5p in HCC. The mRNA expression levels of these targets were calculated by TCGA. (A, C and E) The mRNA levels were significantly downregulated in HCC tissues compared to those in non-cancerous liver tissues. (B, D and F) The relevant relationship between the expression of targets and miR-15b-5p. HCC, hepatocellular carcinoma; TCGA, The Cancer Genome Atlas.](ol-17-02-1695-g16){#f17-ol-0-0-9748}

![mRNA expression levels of two hub target genes of miR-15b-5p in HCC. The mRNA expression levels of these targets were calculated by TCGA. (A and C) The mRNA levels were significantly downregulated in HCC tissues compared to those in non-cancerous liver tissues. (B and D) The relevant relationship between the expression of targets and miR-15b-5p. HCC, hepatocellular carcinoma; TCGA, The Cancer Genome Atlas.](ol-17-02-1695-g17){#f18-ol-0-0-9748}

![Immunohistochemical staining of four hub target genes of miR-15b-5p in HCC. IHC of ACACB, MAP2K1, TLR4 and IGF1 in normal liver tissues and HCC tissues were provided by the HPA. ACACB expression in (A) normal and (B) HCC tissues (antibody HPA006554). MAP2K1 expression in (C) normal and (D) HCC tissues (antibody CAB003834). TLR4 expression in (E) normal and (F) HCC tissues (antibody CAB004025). IGF1 expression in (G) normal and (H) HCC tissues (antibody HPA048946). ACACB had medium staining and moderate intensity in cytoplasmic/membranous normal liver tissues. MAP2K1, TLR4 and IGF1 had low staining and weaker intensity in cytoplasmic/membranous normal liver tissues. By contrast, lower staining and weaker intensity of these hub genes was detected in HCC tissues. Immunohistochemical images were obtained using a microscope (magnification, ×40 or ×400). IHC, immunohistochemistry; HPA, Human Protein Atlas; HCC, hepatocellular carcinoma.](ol-17-02-1695-g18){#f19-ol-0-0-9748}

###### 

Basic information and clinical data of the included studies.

  Accession   Author                        Year   Country   Experiment type                     Platform   HCC numbers   Control numbers   Sample type   TP    FP   FN   TN   (Refs.)
  ----------- ----------------------------- ------ --------- ----------------------------------- ---------- ------------- ----------------- ------------- ----- ---- ---- ---- ----------------------
  GSE57555    Murakami *et al*              2015   Japan     Non-coding RNA profiling by array   GPL18044   5             16                Tissue        2     1    3    15   ([@b20-ol-0-0-9748])
  GSE69580    Hung *et al*                  2015   Taiwan    Non-coding RNA profiling by array   GPL10850   5             5                 Tissue        2     0    3    5    Citation missing
  GSE67882    Ghosh *et al*                 2015   India     Non-coding RNA profiling by array   GPL10850   4             8                 Tissue        5     3    0    4    Citation missing
  GSE54751    Shen *et al*                  2015   USA       Expression profiling by RT-PCR      GPL18262   10            10                Tissue        4     1    6    9    ([@b21-ol-0-0-9748])
  GSE21362    Sato *et al*                  2011   Japan     Non-coding RNA profiling by array   GPL10312   73            73                Tissue        49    24   26   47   ([@b22-ol-0-0-9748])
  GSE22058    Burchard *et al*              2010   USA       Expression profiling by             GPL10457   96            96                Tissue        72    9    24   87   ([@b23-ol-0-0-9748])
  GSE10694    Li *et al*                    2008   China     Non-coding RNA profiling by array   GPL6542    78            10                Tissue        44    5    34   83   ([@b24-ol-0-0-9748])
  GSE12717    Su *et al*                    2008   China     Non-coding RNA profiling by array   GPL7274    5             3                 Tissue        7     1    2    5    ([@b25-ol-0-0-9748])
  GSE40744    Diaz G *et al*                2013   USA       Non-coding RNA profiling by array   GPL14613   10            33                Tissue        7     30   2    37   ([@b26-ol-0-0-9748])
  GSE74618    Martinez-Quetglas I *et al*   2016   Spain     Non-coding RNA profiling by array   GPL14613   218           20                Tissue        139   0    79   20   ([@b27-ol-0-0-9748])
  GSE41874    Morita *et al*                2013   Japan     Non-coding RNA profiling by array   GPL7722    6             4                 Tissue        5     0    1    4    Citation missing
  TCGA                                      2018   USA       miRNA-Seq                           Illumina   375           50                Tissue        285   46   90   4    
  −           Liu *et al*                   2012   China     RT-qPCR                             /          57            59                Serum         27    0    10   31   ([@b15-ol-0-0-9748])
  −           Chen *et al*                  2015   China     RT-qPCR                             /          47            60                Plasma        35    4    4    21   ([@b16-ol-0-0-9748])

HCC, hepatocellular carcinoma; TP, true positivity; FP, false positivity; FN, false negativity; TN, true negativity; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.

###### 

Relationship between the levels of miR-15b-5p and clinicopathological variables in HCC from the TCGA database.

  Parameters           N      Mean value     T-value   P-value
  -------------------- ------ -------------- --------- ---------
  Group                                                
    HCC                375    10.128±0.796   −4.331    \<0.001
    Normal               50   9.823±0.402              
  Sex                                                  
    Male               254    10.072±0.973   1.069     0.009
    Female             122    9.886±1.802              
  Tumor status                                         
    With tumor         152    10.207±0.818   −1.673    0.527
    Tumor-free         201    10.066±0.764             
  Age (years)                                          
    \<60               170    10.100±0.778   −0.424    0.711
    ≥60                201    10.134±0.799             
  Race                                                 
    Caucasian          182    10.074±0.819   −1.199    0.562
    Asian              161    10.176±0.742             
  TNM Stage                                            
    I--II              258    10.119±0.767   0.346     0.203
    III--IV              90   10.085±0.859             
  Pathological Stage                                   
    G1-2               231    10.054±0.754   −2.037    0.922
    G3-4               137    10.226±0.832             
  T stage                                              
    T1-2               276    10.111±0.775   −0.471    0.477
    T3-4                 93   10.156±0.833             

HCC, hepatocellular carcinoma; TCGA, The Cancer Genome Atlas; TNM, tumor-node-metastasis.

###### 

KEGG functional annotation for most significantly related targets of miR-15b-5p.

  Category       Term                                                   Count   P-value
  -------------- ------------------------------------------------------ ------- -------------
  KEGG_PATHWAY   hsa05215: Prostate cancer                              7       1.56×10^−3^
                 hsa04964: Proximal tubule bicarbonate reclamation      4       4.10×10^−3^
                 hsa04610: Complement and coagulation cascades          5       1.68×10^−2^
                 hsa01100: Metabolic pathways                           27      2.18×10^−2^
                 hsa00280: Valine, leucine and isoleucine degradation   4       2.94×10^−2^
                 hsa04015: Rap1 signaling pathway                       8       3.06×10^−2^
                 hsa00220: Arginine biosynthesis                        3       3.26×10^−2^
                 hsa04068: FoxO signaling pathway                       6       4.28×10^−2^

KEGG, Kyoto Encyclopedia of Genes and Genomes.

###### 

GO functional annotation of the target genes of miR-15b-5p.

  GO ID        Category                GO term                                                                                                         P-value       Count
  ------------ ----------------------- --------------------------------------------------------------------------------------------------------------- ------------- -------
  GO:0060347   GO_Biological process   Heart trabecula formation                                                                                       5.26×10^−4^   4
  GO:0001657   GO_Biological process   Ureteric bud development                                                                                        9.93×10^−4^   5
  GO:0006520   GO_Biological process   Cellular amino acid metabolic process                                                                           1.21×10^−3^   5
  GO:0032354   GO_Biological process   Response to follicle-stimulating hormone                                                                        1.34×10^−3^   3
  GO:0000187   GO_Biological process   Activation of MAPK activity                                                                                     1.64×10^−3^   7
  GO:0032754   GO_Biological process   Positive regulation of interleukin-5 production                                                                 1.99×10^−3^   3
  GO:0006814   GO_Biological process   Sodium ion transport                                                                                            2.63×10^−3^   6
  GO:0010951   GO_Biological process   Negative regulation of endopeptidase activity                                                                   3.04×10^−3^   7
  GO:0008652   GO_Biological process   Cellular amino acid biosynthetic process                                                                        3.39×10^−3^   4
  GO:0019221   GO_Biological process   Cytokine-mediated signaling pathway                                                                             4.49×10^−3^   7
  GO:0005615   GO_Cellular component   Extracellular space                                                                                             4.20×10^−3^   28
  GO:0005759   GO_Cellular component   Mitochondrial matrix                                                                                            5.27×10^−3^   11
  GO:0005886   GO_Cellular component   Plasma membrane                                                                                                 6.97×10^−3^   65
  GO:0005887   GO_Cellular component   Integral component of plasma membrane                                                                           7.97×10^−3^   28
  GO:0005578   GO_Cellular component   Proteinaceous extracellular matrix                                                                              1.37×10^−2^   9
  GO:0005576   GO_Cellular component   Extracellular region                                                                                            2.18×10^−2^   29
  GO:0009986   GO_Cellular component   Cell surface                                                                                                    2.59×10^−2^   13
  GO:0045211   GO_Cellular component   Postsynaptic membrane                                                                                           3.79×10^−2^   7
  GO:0005739   GO_Cellular component   Mitochondrion                                                                                                   3.85×10^−2^   24
  GO:0009897   GO_Cellular component   External side of plasma membrane                                                                                3.93×10^−2^   7
  GO:0004908   GO_Molecular function   Interleukin-1 receptor activity                                                                                 2.79×10^−3^   3
  GO:0008201   GO_Molecular function   Heparin binding                                                                                                 2.91×10^−3^   8
  GO:0004867   GO_Molecular function   Serine-type endopeptidase inhibitor activity                                                                    5.81×10^−3^   6
  GO:0042803   GO_Molecular function   Protein homodimerization activity                                                                               5.89×10^−3^   18
  GO:0001078   GO_Molecular function   Transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding   1.01×10^−2^   6
  GO:0005088   GO_Molecular function   Ras guanyl-nucleotide exchange factor activity                                                                  1.17×10^−2^   6
  GO:0004860   GO_Molecular function   Protein kinase inhibitor activity                                                                               2.34×10^−2^   4
  GO:0002114   GO_Molecular function   Interleukin-33 receptor activity                                                                                2.34×10^−2^   2
  GO:0004854   GO_Molecular function   Xanthine dehydrogenase activity                                                                                 2.34×10^−2^   2
  GO:0051537   GO_Molecular function   2 iron, 2 sulfur cluster binding                                                                                3.47×10^−2^   3

GO, gene ontology.

###### 

GO functional annotation of the hub genes of miR-15b-5p in HCC.

  GO ID        Category    Term                                                         P-value       Count
  ------------ ----------- ------------------------------------------------------------ ------------- -------
  GO:0000187   GOTERM_BP   Activation of MAPK activity                                  2.39×10^−4^   3
  GO:0070371   GOTERM_BP   ERK1 and ERK2 cascade                                        5.71×10^−3^   2
  GO:0006928   GOTERM_BP   Movement of cell or subcellular component                    2.03×10^−2^   2
  GO:0051092   GOTERM_BP   Positive regulation of NF-κB transcription factor activity   3.13×10^−2^   2
  GO:0010629   GOTERM_BP   Negative regulation of gene expression                       3.22×10^−2^   2
  GO:0070374   GOTERM_BP   Positive regulation of ERK1 and ERK2 cascade                 4.10×10^−2^   2
  GO:0010628   GOTERM_BP   Positive regulation of gene expression                       6.10×10^−2^   2
  GO:0005524   GOTERM_MF   ATP binding                                                  4.17×10^−2^   3
  GO:0005515   GOTERM_MF   Protein binding                                              7.33×10^−2^   5
  GO:0004672   GOTERM_MF   Protein kinase activity                                      8.24×10^−2^   2
  GO:0004674   GOTERM_MF   Protein serine/threonine kinase activity                     8.62×10^−2^   2

GO, gene ontology; HCC, hepatocellular carcinoma; BP, biological process; MF, molecular function; CC, cellular component.

###### 

KEGG pathway analysis of the hub genes of miR-15b-5p in HCC.

  Category       Term                                                Count   P-value       Genes
  -------------- --------------------------------------------------- ------- ------------- --------------------
  KEGG_PATHWAY   hsa04066: HIF-1 signaling pathway                   3       5.92×10^−4^   MAP2K1, IGF1, TLR4
  KEGG_PATHWAY   hsa05205: Proteoglycans in cancer                   3       2.45×10^−3^   MAP2K1, IGF1, TLR4
  KEGG_PATHWAY   hsa04151: PI3K-Akt signaling pathway                3       7.21×10^−3^   MAP2K1, IGF1, TLR4
  KEGG_PATHWAY   hsa04730: Long-term depression                      2       2.58×10^−2^   MAP2K1, IGF1
  KEGG_PATHWAY   hsa05214: Glioma                                    2       2.80×10^−2^   MAP2K1, IGF1
  KEGG_PATHWAY   hsa05218: Melanoma                                  2       3.05×10^−2^   MAP2K1, IGF1
  KEGG_PATHWAY   hsa04914: Progesterone-mediated oocyte maturation   2       3.73×10^−2^   MAP2K1, IGF1
  KEGG_PATHWAY   hsa05215: Prostate cancer                           2       3.77×10^−2^   MAP2K1, IGF1
  KEGG_PATHWAY   hsa04620: Toll-like receptor signaling pathway      2       4.53×10^−2^   MAP2K1, TLR4
  KEGG_PATHWAY   hsa04114: Oocyte meiosis                            2       4.66×10^−2^   MAP2K1, IGF1

KEGG, Kyoto Encyclopedia of Genes and Genomes; HCC, hepatocellular carcinoma.
